Home › Articles › Volume 7, Issue 3 › Changes in Liver Stiffness and Steatosis in Patients...
Moradabad, India
Original Article
Pharmacy

Changes in Liver Stiffness and Steatosis in Patients with Chronic Hepatitis C during the Clinical Course of Daclatasvir/ Velpatasvir Therapy: A Prospective Observational Study


Volume 7, Issue 3, Pages 1-5

Authors

Megha Garg1, Aseem Sethi2, Rohit Kumar Varshney3
Affiliation:
1Intern, Department of Pharmacy Practice, Teerthanker Mahaveer College of Pharmacy, TMU, Moradabad, U.P, India,
2Student, Department of Pharmacy Practice, Indo-Soviet Friendship College of Pharmacy, Moga, Punjab, India,
3Associate Professor, Department of Anaesthesia, Teerthanker Mahaveer College of Pharmacy, TMU, Moradabad, U.P, India.

Corresponding Author

Rohit Kumar Varshney

Abstract

Background: The mechanism behind reduction of liver fibrosis and steatosis in Chronic Hepatitis C (CHC) patients receiving interferon-free Direct Acting Antiviral Agent (DAA) therapy is still unclear. Non-invasive techniques such as Transient Elastography (TE) and Controlled Attenuation Parameter (CAP) are used to evaluate the chronological changes in liver stiffness and steatosis, respectively, in CHC patients receiving DAA therapy. Subjects and Methods: The study involves 50 CHC patients receiving Daclatasvir or Velpatasvir (DCV/VEL) in whom liver stiffness and steatosis was measured using TE and CAP, respectively. Laboratory investigational data, liver stiffness, and steatosis were recorded at baseline (prior to therapy), week 12 (post initiation of therapy), End of Treatment (EOT), and week 24 (post initiation of therapy). Analysis was performed 12 weeks post completion of therapy (SVR 12). Results: Significant difference was observed in laboratory parameters such as aminotranferases, serum albumin, platelet count, and α-fetoprotein at each time point of study as compared to the baseline. A highly statistically significant difference was observed in laboratory parameters when calculated as overall (P<0.001). Liver stiffness reduced significantly at baseline vs week 12 (P=0.044), week 12 vs EOT (P=0.011), baseline vs week 24 (P<0.001) (overall P<0.001). However, steatosis showed an insignificant difference (overall P=0.325). Conclusion: A significant overall decrease was observed in liver stiffness among patients with chronic hepatitis C during the clinical course of Daclatasvir/ Velpatasvir therapy. Steatosis reduced considerably, however the results were found to be statistically insignificant.

Keywords

Chronic Hepatitis C, Liver Stiffness, Daclatasvir, Velpatasvir.

History

Received 01 August 2018

Accepted 01 September 2018

DOI

10.21276/ajmr.2018.7.3.MC1

Author Notes

Corresponding Author: Dr. Rohit Kumar Varshney, Associate Professor, Department of Anaesthesia, Teerthanker Mahaveer College of Pharmacy, TMU, Moradabad, U.P, India.

Open Access

It is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. https://creativecommons.org/licenses/by-nc/4.0/

Copyright

Copyright (c) 2018 Asian Journal of Medical Research

Cite this Article

Formats

                                                
Actions
Download PDF
Metrics
8
Downloads
8
Views
Journal
Journal Asian Journal of Medical Research
Volume Volume 7
Issue Issue 3
Year 2018

Purchase access plans

Select the plan that best fits your need

Loading plans...

Statistics:

Views: 0
Downloads: 0

Asian Journal of Medical Research (AJMR) is an international, peer-reviewed, quarterly open-access journal publishing advanced research across medical specialties.

Quick Links

For Authors

© 2026 Asian Journal of Medical Research. All Rights Reserved.Designed and Developed By Kryoni